长春高新(000661.SZ)子公司两款药品新纳入国家医保目录

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has two products newly included in the National Medical Insurance Directory for 2025, which may enhance the company's market position and revenue potential [1] Group 1 - The products included are Jinsai Zeng (now known as "Jin Pei Growth Hormone Injection") and Meishiya (known as "Medroxyprogesterone Acetate Oral Suspension") [1] - The inclusion in the National Medical Insurance Directory indicates a significant regulatory approval that could lead to increased accessibility and demand for these medications [1]